

Literatur zu Weckmann, Chenot

- Schmiegel W, Pox CP. S3-Leitlinie Kolo-
rektales Karzinom (Konsultationsfas-
sung) Version 1.0, 01.2013. Leitlini-
enprogramm Onkologie. AMWF-Regis-
ter-Nummer (021/007OL)
- Husmann G, Kaatsch P, Katalinic A, et al.
Robert Koch Institut – Krebs in Deutsch-
land 2007/2008 Häufigkeiten und
Trends. RKI und GEKD 2012
- Jaspersen KW, Tuohy TM, Neklason DW,
Burt RW. Hereditary and familial colon
cancer. *Gastroenterology* 2010; 138:
2044–58
- Aarnio M, Mecklin JP, Aaltonen LA, Ny-
ström-Lahhti M, Järvinen HJ. Life-time
risk of different cancers in hereditary
non-polyposis colorectal cancer
(HNPCC) syndrome. *Int J Cancer*. 1995;
64: 430–3
- Gibbons DC, Sinha A, Phillips RK, Clark
SK. Colorectal cancer: no longer the issue
in familial adenomatous polyposis? *Fam
Cancer*. 2011; 10 : 11–20
- Pischoon T, Lahmann PH, Boeing H, et al.
Body size and risk of colon and rectal
cancer in the European Prospective In-
vestigation Into Cancer and Nutrition
(EPIC). *J Natl Cancer Inst* 2006; 98:
920–31
- Woodward M, Huxley R. Obesity and risk
of colorectal cancer: a meta-analysis of 31
studies with 70,000 events. *Cancer Epi-
demiol Biomarkers Prev* 2007; 16:
2533–47
- Dai Z, Xu YC, Niu L. Obesity and colo-
rectal cancer risk: a meta-analysis of co-
hort studies. *World J Gastroenterol*.
2007; 13: 4199–206
- Wang Y, Jacobs EJ, Patel AV, et al. A pro-
spective study of waist circumference and
body mass index in relation to colo-
rectal cancer incidence. *Cancer Causes
Control* 2008; 19: 783–792
- Larsson SC, Wolk A. Obesity and colon
and rectal cancer risk: a meta-analysis of
prospective studies. *Am J Clin Nutr* 2007;
86: 556–65
- Tsoi KKF, Pau CYY, Wu WKK, Chan FKL,
Griffiths S, Sung J. Cigarette smoking and
the risk of colorectal cancer: A meta-ana-
lysis of prospective cohort studies. *Clin
Gastroenterol Hep* 2009; 6: 682–88
- Leufkens AM, Van Duijnhoven FJ, Sierse-
ma PD, et al. Cigarette smoking and colo-
rectal cancer risk in the European Pro-
spective Investigation into Cancer and
Nutrition study. *Clin Gastroenterol He-
patol*. 2011; 9: 137–44
- Knekt P, Hakama M, Järvinen R, Pukkala
E, Heliövaara M. Smoking and risk of co-
lorectal cancer. *Br J Cancer*. 1998; 78:
136–9
- Liang PS, Chen T-Y and Giovannucci E.
Cigarette smoking and colorectal cancer
incidence and mortality: systematic re-
view and meta-analysis. *Int J Cancer*
2008; 124: 2406–15
- Hoffmeister M, Schmitz S, Kamrodt E, et
al. Male sex and smoking have a larger
impact on the prevalence of colorectal
neoplasia than family history of colo-
rectal cancer. *Clin Gastroenterol Hepatol*
2010; 8: 870–6
- Boyle T, Keegel T, Bull F, Heyworth J, Frit-
schi L. Physical activity and risks of pro-
ximal and distal colon cancers: a syste-
matic review and meta-analysis. *J Natl
Cancer Inst*. 2012; 104: 1548–61
- Doubeni CA, Major JM, Laiyemo AO, et
al. Contribution of behavioral risk factors
and obesity to socioeconomic differ-
ences in colorectal cancer incidence. *J
Natl Cancer Inst*. 2012; 104: 1353–62
- Isa ZM, Shah SA. Dietary patterns and
risk of colorectal cancer: a systematic re-
view of cohort studies (2000–2011). *Asi-
an Pac J Cancer Prev*. 2012; 13: 4713–7
- Huxley RR, Ansary-Moghaddam A, Clif-
ton P, Czernichow S, Parr CL, Woodward
M. The impact of dietary and lifestyle risk
factors on risk of colorectal cancer: a
quantitative overview of the epidemiologi-
cal evidence. *Int J Cancer*. 2009; 125:
171–80
- Wu S, Feng B, Li K, et al. Fish consump-
tion and colorectal cancer risk in humans:
a systematic review and meta-analysis.
Am J Med 2012; 125: 551–9
- Magalhães B, Peleteiro B, Lunet N. Dieta-
ry patterns and colorectal cancer: syste-
matic review and meta-analysis. *Eur J
Cancer Prev*. 2012; 21: 15–23
- Kirkegaard H, Johnsen NF, Christensen J,
Frederiksen K, Overvad K, Tjønneland A.
Association of adherence to lifestyle re-
commendations and risk of colorectal
cancer: a prospective Danish cohort stu-
dy. *BMJ* 2010; 341: c5504
- Astin M, Griffin T, Neal RD, Rose P, Ham-
ilton W. The diagnostic value of symp-
toms for colorectal cancer in primary care:
a systematic review. *Br J Gen Pract*.
2011; 61: e231–43
- Adelstein B-A, Macaskill P, Chan SF, Kate-
laris PH, Irwig L. Most bowel cancer
symptoms do not indicate colorectal
cancer and polyps: a systematic review.
BMC Gastroenterology 2011, 11: 65
- Domagalski L, Gesenhues S. *Onkologie*.
In: Gesenhues S, Ziesché R (Hrsg.). *Praxis-
leitfaden Allgemeinmedizin*, 5. Aufl.
München: Elsevier, 2006: 1489–98
- Fischer T, Huhn W, Freitag MH. Obstipa-
tion. In Kochen M (Ed.). *Duale Reihe:
Allgemeinmedizin und Familienmedi-
zin*, 4. Aufl. Stuttgart: Thieme, 2012:
350–56
- Bundesministerium für Gesundheit. Be-
kanntmachung des Bundesausschusses
der Ärzte und Krankenkassen über eine
Änderung der Richtlinien über die Früh-
erkennung von Krebserkrankungen
(Krebsfrüherkennungs-Richtlinien) vom
21. Juni 2002.
- Riens B, Schäfer M, Altenhofen L. Teil-
nahmeraten zur Beratung über Darm-
krebs und zur Früherkennung im regio-
nalen Vergleich. Zentralinstitut für die
kassenärztliche Versorgung in Deutsch-
land, 2011
- Duffy MJ, Van Rossum LGM, Van Turen-
hout ST, et al. Use of faecal markers in
screening for colorectal neoplasia: a Eu-
ropean group on tumor markers position
paper. *Int J of Cancer* 2011 Jan 1; 128:
3–11
- Hewitson P, Glasziou P, Watson E, Towler
B, Irwig L. Cochrane systematic review of
colorectal cancer screening using the fecal
occult blood test (Hemoccult): an update.
Am J Gastroenterol 2008; 103: 1541–9
- Brenner H, Arndt V, Stürmer T, Stegmaier
C, Ziegler H, Dhom G. Long-lasting re-
duction of risk of colorectal cancer follo-
wing screening endoscopy. *Br J Cancer*
2001; 85: 972–6
- Shaukat A, Mongin SJ, Geisser MS, et al.
Long-term mortality after screening for
colorectal cancer. *N Engl J Med* 2013;
369: 1106–14
- Whitlock EP, Lin JS, Liles E, Beil TL, Fu R.
Screening for colorectal cancer: a targe-
ted, updated systematic review for the
U.S. Preventive Services Task Force. *Ann
Intern Med*. 2008;149: 638–58
- Oort FA, Terhaar Sive Droste JS, Van der
Hulst RW, et al. Colonoscopy-controlled
intra-individual comparisons to screen
relevant neoplasia: faecal immunoche-
mical test vs. guaiac-based faecal occult
blood test. *Aliment. Pharmacol Ther*
2010; 31: 432–39
- Lieberman DA, Weiss DG. One-time
screening for colorectal cancer with com-
bined fecal occult-blood testing and
examination of the distal colon. *NEJM*
2001; 345: 555–60
- Rosman AS, Korsten MA. Effect of verifi-
cation bias on the sensitivity of fecal oc-
cult blood testing: a meta-analysis. *J Gen
Intern Med* 2010; 25: 1211–21
- Pignone M, Campbell MK, Carr C, Phil-
lips C. Meta-analysis of dietary restric-
tion during fecal occult blood testing. *Eff-
Clin Pract* 2001, 4: 150–6
- Konrad G. Dietary interventions for fecal
occult blood test screening: systematic
review of the literature. *Can Fam Physi-
cian* 2010; 56: 229–38
- Konrad G, Katz A. Practical advice based
on a systematic review of the literature.
Are medication restrictions before FOBT
necessary? *Can Fam Phys* 2012; 9:
939–48
- Cole SR, Young GP. Effect of dietary res-
triction on participation in faecal occult
blood test screening for colorectal cancer.
Med J Aust 2001; 175: 195–8
- Jellema P, Van der Windt DAWM, Bruin-
vels DJ, et al. Value of symptoms and ad-
ditional diagnostic tests for colorectal

- cancer in primary care: systematic review and meta-analysis. *BMJ* 2010; 340: c1269
42. Mandelli G, Radaelli F, Paggi S, et al. Anti-coagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. *Eur J Gastroenterol Hepatol.* 2011; 23: 323–6
 43. Carlson CM, Kirby KA, Casadei MA, Partin MR, Kistler CE, Walter LC. Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow-up? *Arch Intern Med* 2011; 171: 249–56
 44. Van Rossum LG, Vn Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. *Gastroenterology* 2008; 135: 82–90
 45. Webendörfer S, Messerer P, Eberle F, Zober A. Eine Initiative sekundärer Prävention in der BASF Aktiengesellschaft. *Dtsch Med Wochenschr.* 2004; 129: 239–43
 46. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. *J Natl Cancer Inst* 2007; 99: 162–70
 47. Terhaar sive Droste JX, Van Turenhout ST, Oort FA, et al. Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study. *BMC Gastroenterol* 2012; 12: 94
 48. Trojan J, Povse N, Schröder O, Stein J. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. *Z Gastroenterol.* 2002; 40: 921–4
 49. Health Quality Ontario. Faecal occult blood test for colorectal cancer screening: an evidence-based analysis. *Ont Health Technol Assess Ser.* 2009; 9: 1–40
 50. Tao S, Brenner H. Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening. *Eur J Cancer Prev* 2013; 22: 305–10
 51. <http://www.rijksoverheid.nl/onderwerpen/bevolkingsonderzoek/documenten-en-publicaties/kamerstukken/2011/06/01/kamerbrief-invoering-bevolkingsonderzoek-darmkanker.html> (letzter Zugriff am 21.03.2013)
 52. http://www.zorg-en-gezondheid.be/uploadedFiles/NLsite_v2/Beleid/Adviesvraag%20Vlaams%20bevolkingsonderzoek%20naar%20dikdarmkanker.pdf (letzter Zugriff am 08.03.2013)
 53. Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. *B J Cancer* 2008; 99, 133–5
 54. Ahmed D, Danielsen SA, Aagesen TH, et al. A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. *Clin Transl Gastroenterol.* 2012; 3: e27
 55. Lind GE, Danielsen SA, Ahlquist T, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. *Mol Cancer* 2011; 10: 85
 56. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. *Gastroenterology* 2012; 142: 248–56
 57. Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. *BMC Med* 2011; 9: 133
 58. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. *Gastroenterology* 2007; 132: 96–102
 59. Van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, Van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. *Am J Gastroenterol* 2006; 101: 343–50
 60. Heresbach D, Barrioz T, Lapalus MG, et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. *Endoscopy* 2008; 40: 284–90
 61. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. *Gastroenterology* 1997; 112: 24–8
 62. Beloesky Y, Brinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in the elderly patients. *Arch Intern Med* 2003; 163: 803–08
 63. Lichtenstein GR, Cohen LB, Uribarri J. Review article: bowel preparation for colonoscopy – the importance of adequate hydration. *Aliment Pharmacol Ther* 2007; 26: 633–41
 64. Riphaut A, Wehrmann T, Weber B, et al. S3-Leitlinie „Sedierung in der gastrointestinalen Endoskopie“ 2008. S3-Guidelines (AMWF-Register-Nr. 021/014)
 65. Friedrich K, Stremmel W, Sieg A. Endoscopist-administered propofol sedation is safe – prospective evaluation of 10,000 patients in an outpatient practice. *J Gastrointest Liver Dis* 2012; 3: 259–63
 66. De Jonge V, Sint Nicolaas J, Van Baalen O, et al. The incidence of 30-day adverse events after colonoscopy among outpatients in the Netherlands. *Am J Gastroenterol* 2012; 107: 878–84
 67. Ross WA. Colorectal cancer screening in evolution: Japan and the USA. *J Gastroenterol Hepatol* 2010; 25 (Suppl 1): S49–56
 68. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. *Gastroenterology* 2008; 135: 1899–906
 69. Ko CW, Riffle S, Michaels L, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. *Clin Gastroenterol Hepatol* 2010; 8: 166–73
 70. Suissa A, Bentur OS, Lachter J, et al. Outcome and complications of colonoscopy: a prospective multicenter study in Northern Israel. *Diagn Ther Endosc* 2012; 2012: 612542
 71. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. *Gastrointest Endosc* 2011; 4: 885–97
 72. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. *Ann Intern Med* 2006; 145: 880–6
 73. Ferlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas, advanced adenomas and colorectal cancer in individuals undergoing screening colonoscopy. *JAMA* 2011; 306: 1352–58
 74. Pan A, Schlup M, Lübcke R, Chou A, Schultz M. The role of aspirin in post-polypectomy bleeding – a retrospective survey. *BMC Gastroenterol* 2012; 12: 138
 75. Manocha D, Singh M, Mehta N, Murthy UK. Bleeding risk after invasive procedures in aspirin/NSAID users: polypectomy study in veterans. *Am J Med.* 2012; 125: 1222–7
 76. Feagins LA, Uddin FS, Davila RE, Harford WV, Spechler SJ. The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. *Dig Dis Sci* 2011; 56: 2631–8
 77. Wood JJ, Foy CJ, Valori R, et al. Does use of a colonoscopy imaging device improve performance? A cohort study. *Surg Endosc* 2012; 26: 3616–21
 78. Zorzi M, Baracco S, Fedato C, et al. Screening for colorectal cancer in Italy, 2009 survey. *Epidemiol Prev* 2011; 35 (5–6 Suppl 5): 55–77
 79. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med* 2009; 150: 1–8
 80. Leung K, Pinsky P, Laiyemo AO, et al. Ongoing colorectal cancer risk despite surveillance colonoscopy: the Polyp Prevention Trial Continued Follow-up Study. *Gastrointest Endosc* 2010; 71: 111–7
 81. Rex DK, Cummings OW, Helper DJ, et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment]. *Gastroenterology* 1996; 111: 1178–81
 82. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. *Ann Intern Med* 2013; 158: 312–20
 83. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect

- of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2012; 9: e1001352
84. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial – SCORE. *J Natl Cancer Inst* 2011; 103: 1310–22
85. Atkin W, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicenter randomized controlled trial. *Lancet* 2010; 375: 1624–33
86. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. *Br J Surg* 2012; 99: 1488–500
87. Mang T, Schima W. CT-Kolonographie. Stuttgart: Thieme 2009
88. Wijkerslooth de Weerdesteijn TR. Population screening for colorectal cancer by colonoscopy (Dissertation). Amsterdam: UvA-DARE, 2013
89. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centers. *Gut* 1988; 29: 206–17
90. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; 48: 526–35
91. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998–2010. *Gastroenterology* 2012; 143: 382–9
92. Selinger CP, Andrews JM, Titman A, et al. Long-term follow up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2013. pii: S1542-3565(13)00708-8
93. Jess T, Simonsen J, Jørgensen KT, Vestergaard Pedersen B, Munk N, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. *Gastroenterology* 2012; 143: 375–81
94. Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. *Gastroenterology* 2009; 136: 1561–7
95. Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. *Gastroenterology* 2006; 10: 1039–46
96. Shaikat A, Virmig DJ, Salfiti NI, Howard DH, Sitaraman SV, Liff JM. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the United States? A population-based case-control study. *Dig Dis Sci* 2011; 56: 2378–83
97. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. *Aliment. Pharmacol Ther* 2006; 23: 1097–104
98. Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. *Scand J Gastroenterol* 2009; 44: 46–55
99. Mooiweer E, Baars JE, Lutgens MWMD, et al. Disease severity does not affect the interval between IBD diagnosis and the development of CRC: Results from two large, Dutch case series. *J Crohns Colitis* 2012; 4: 435–40
100. Nguyen GC. A tale of two cohorts: are we overestimating the risk of colorectal cancer in inflammatory bowel disease? *Gastroenterology* 2012; 143: 288–90
101. Lukas M. Inflammatory Bowel Disease as a risk factor for colorectal cancer. *Dig Dis* 2010; 28: 619–24
102. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. *Gastroenterol Clin North Am* 2006; 35: 675–712
103. Cooper K, Squires H, Carrol C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. *Health Technology Assess* 2010; 14: 1–206
104. Butterworth JR. Chemoprevention of colorectal cancer in inflammatory bowel disease. *Digest Liv Dis* 2009; 41: 338–9
105. Söderlund S, Granath F, Broström O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. *Gastroenterology* 2010; 138: 1697–703
106. Asklung J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. *Gastroenterology* 2001; 120: 1356–62
107. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. *Am J Gastroenterol* 2001; 96: 2992–3003
108. Butterworth AS, Higgins JPT, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: A meta-analysis. *Eur J Cancer* 2006; 42: 216–27
109. Hall NR, Bishop DT, Stephenson BM, Finnan PJ. Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk. *Dis Colon Rectum* 1996; 39: 739–43
110. Ait Ouakrim D, Lockett T, Boussioutas A, et al. Screening participation predictors for people at familial risk of colorectal cancer: a systematic review. *Am J Prev Med* 2013; 44: 496–506
111. Burn J, Mathers J, Bishop DT. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). *Recent Results Cancer Res* 2013; 191: 157–83
112. Holinski-Feder E, Morak M. Familiäre adenomatöse Polyposis und andere Polyposissyndrome. *Gastroenterologie* 2010; 5: 7–15
113. Win AK, Lindor NM, Winship I, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. *J Natl Cancer Inst* 2013; 105: 274–9
114. Lamberti C, Mangold E, Pagenstecher C, et al. Frequency of hereditary non-polypoid colorectal cancer among unselected patients with colorectal cancer in Germany. *Digestion* 2006; 74: 58–67
115. Van Lier MG, Leenen CH, Wagner A, et al. Yield of routine molecular analyses in colorectal cancer patients ≤ 70 years to detect underlying Lynch syndrome. *J Pathol* 2012; 226: 764–74
116. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol* 2008; 26: 5783–8
117. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; 96: 261–8
118. Griffith JM, Lewis CL, Brenner AR, Pignone MP. The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial. *BMC Med Inform Decis Mak* 2008 Jan 24; 8: 4
119. Jimbo M, Rana G, Hawley S, et al. What is lacking in current decision aids on cancer screening? *Ca Cancer J Clin* 2013; 63: 193–214
120. Waldmann A, Raspe H, Katalinic A. Darmkrebsrisiko bei familiären und hereditären Risikopersonen unter 55 Jahren. *Z Gastroenterol* 2009; 47: 1052–8
121. Barret B, McKenna P. Communicating benefits and risks of screening for prostate, colon, and breast cancer. *Fam Med* 2011; 43: 248–53
122. Galesic M, Gigerenzer S, Strauinger N. Natural frequencies help older adults and people with low numeracy to evaluate medical screening tests. *Med Decis Mak* 2009; 29: 368–71
123. Lewis CL, Golin CE, DeLeon C, et al. A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial. *BMC Med Inform Decis Mak* 2010; 10: 54
124. Steckelberg A, Mühlhauser I. Darmkrebs Screening Früherkennung. Universität Hamburg, 2008
125. Steckelberg A, Hülfenhaus C, Haastert B, Mühlhauser I. Effect of evidence based risk information on „informed choice“ in colorectal cancer screening: randomised controlled trial. *BMJ* 2011; 342: d3193